-
Read the transcript from Wednesday's hearing before Judge Matthew Kacsmaryk in a federal case that could decide the future of access to a major abortion pill.
-
A new bill in the California Legislature would give legal protections to doctors who mail abortion pills to patients in other states.
-
If the case succeeds, it could have sweeping repercussions — for abortion providers and patients across the nation, as well as for the FDA's drug-approval process.
-
California Gov. Gavin Newsom said that the state would halt business with Walgreens after the pharmacy giant agreed to stop distributing mifepristone in some red states amid legal pressure.
-
The drugstore chain’s announcement that access to mifepristone may not expand as broadly as federal regulators intended when they finalized a rule change allowing more pharmacies to provide the pill. Here’s a closer look at the issue.
-
The suit comes as a federal judge in another case is considering whether to overturn FDA approval of the same drug, mifepristone.
-
The state sent an email to all state medical providers about abortion medication and the criminal penalties surrounding it.
-
In the wake of an FDA decision that allows pharmacies to stock the medication, the Florida agency warned providers that “criminal penalties” could result over violations.
-
Changes by the FDA mean patients won't have to schedule in-person exams to get a prescription. That opens the door for more pharmacies to provide the medication. But not everyone will have access.
-
The FDA finalized a rule change that broadens availability of abortion pills to many more pharmacies, including large chains and mail-order companies.